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Abstract
In 2009, the European Centre for Disease Prevention and Control initiated the ‘Burden of Communicable Diseases in Europe
(BCoDE)’ project to generate evidence-based and comparable burden-of-disease estimates of infectious diseases in Europe.
The burden-of-disease metric used was the Disability-Adjusted Life Year (DALY), composed of years of life lost due to
premature death (YLL) and due to disability (YLD). To better represent infectious diseases, a pathogen-based approach was
used linking incident cases to sequelae through outcome trees. Health outcomes were included if an evidence-based causal
relationship between infection and outcome was established. Life expectancy and disability weights were taken from the
Global Burden of Disease Study and alternative studies. Disease progression parameters were based on literature. Country-
specific incidence was based on surveillance data corrected for underestimation. Non-typhoidal Salmonella spp. and
Campylobacter spp. were used for illustration. Using the incidence- and pathogen-based DALY approach the total burden
for Salmonella spp. and Campylobacter spp. was estimated at 730 DALYs and at 1,780 DALYs per year in the Netherlands
(average of 2005–2007). Sequelae accounted for 56% and 82% of the total burden of Salmonella spp. and Campylobacter
spp., respectively. The incidence- and pathogen-based DALY methodology allows in the case of infectious diseases a more
comprehensive calculation of the disease burden as subsequent sequelae are fully taken into account. Not considering
subsequent sequelae would strongly underestimate the burden of infectious diseases. Estimates can be used to support
prioritisation and comparison of infectious diseases and other health conditions, both within a country and between
countries.
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Introduction
The disability-adjusted life year (DALY), a metric quantifying
and combining the impact of premature death and non-fatal
health outcomes resulting from disease, was jointly developed by
the World Bank, Harvard School of Public Health and the World
Health Organization for the Global Burden of Disease and injury
(GBD) study [1–4]. DALYs were developed with the aim of
supporting priority setting for healthcare and health research, to
identify disadvantaged groups for targeted healthcare interven-
tions, and to provide a comparable output measure for interven-
tions, evaluations and planning [4]. Since their development and
introduction in the World Development Report [5] DALYs have
been widely used in both national and global disease burden
estimations (e.g. [6–10]).
In Europe, infectious diseases were estimated to account for less
than 10% of the total burden of disease as measured by DALYs
[11]. However, this figure might underestimate the true burden of
infectious diseases as subsequent sequelae were not fully taken into
account in most previously conducted disease burden assessments
[12]. To get a better insight into the true disease burden in Europe
[13–15], the European Centre for Disease Prevention and Control
(ECDC) launched the Burden of Communicable Diseases in the
European Union, EEA and EFTA countries (BCoDE) project in
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2009. This project aims to generate evidence-based, robust and
comparable disease burden estimates of infectious diseases in
Europe. The methodology applied is presented in this current
paper, using non-typhoidal Salmonella spp. and Campylobacter spp.
for illustration.
Methodology
The term ‘‘Burden of disease’’ refers to a quantitative estimation
of the impact of diseases on a population or geographical region,
using a multitude of indicators. For the BCoDE-project, a disease
burden-indicator was needed that captures and weighs the impact
of acute illness due to infectious diseases and associated sequelae
on morbidity and mortality in a single metric, thereby allowing the
comparison between infectious diseases within and between
countries, and with other health conditions. In addition, methods
adopted by the BCoDE-project should allow future development
towards a methodology that accounts for the dynamic nature of
infectious diseases and impact of intervention(s) [12]. As economic
analyses were not foreseen, non-monetary measures were
favoured; of these Quality-Adjusted Life Years (QALY) and
Disability-Adjusted Life Years (DALY) are the most prominent
metrics [16–19]. QALYs are used in health economics in high-
income countries (including Europe) [20]. DALYs are used
worldwide, for all age-classes and various health conditions [21].
QALYs represent survival that is down-weighed for the time lived
with functional capacity, whereas DALYs are a health gap
measure which directly quantifies health loss, and therefore is a
more straightforward burden of disease measure, underpinning
our choice for the DALY methodology.
Disability-Adjusted Life Years
The DALY was introduced by Murray and co-workers in the
GBD-study [4,22]. It is composed of a measure for the number of
years of life lost due to premature death (YLL) and the number of
years of life lost due to disability (YLD). The DALY, as a
normative measure, quantifies the health losses (in years) based on
the difference between the observed and ideally expected
population-based health goal [3]. YLD are computed by weighing
each remaining life year with a factor (disability weight) between 0
(perfect health) and 1 (death) depending on the severity of the
concerning disability.
YLD are calculated as the product of the duration of the illness
(t) and the disability weights (w) of a specific health outcome,





na,sl  t~a,sl  w~a,sl ,
where t, w and n for health outcome l may be age-dependent (a)
and/or sex-dependent (s), where a stands for age at infection and a˜
for age at disease onset and death. For more details see File S1.
YLL for a specific health outcome are calculated by summation
of the number of all fatal cases (d) due to the health outcome (l) at
age (a), each case multiplied by the remaining individual life
expectancy (e) at the age of death a˜. d for health outcome l may be






The DALY is then calculated as the sum of the YLL and YLD
(for more details File S1).
Applying the DALY methodology requires decisions reflecting
on value choices. To assure comparability to other disease burden-
assessments all YLL estimates are based on the Coale and Demeny
West Level 26 and 25 life tables. Regarding disability weights, we
relied on the GBD-study, where available, supplemented by
disability weights from other studies with methods similar to the
GBD assessments [23]. Durations of health outcomes, possibly
age- and/or sex-dependent, were based on published literature.
Time-discounting and age-discounting was not applied.
Incidence- and Pathogen-based DALY
The DALY can be calculated using different methodological
approaches. The correct assignment of disease burden to the
causal event is important for the estimation of disease burden for
infectious diseases in order to provide thorough and reliable
estimates. To attribute all health consequences of an infection to
the initial infectious event, and therefore estimate the complete
burden caused by this infection decisions are required on whether
or not sequelae are causally linked to the infection. In the
incidence- and pathogen-based DALY approach [12–14,24–26]
sequelae, for which there is sufficient evidence for causal
relationship, are related to the initial infection by means of an
outcome tree representing the natural history of the infection and
its short- and long-term sequelae (File S1).
Outcome Tree
In order to assess the disease burden for the selected pathogens,
- in total 32 pathogens (see Kretzschmar et al. [12]) -, the different
health outcomes following infection with a particular agent were
defined. These health outcomes were described in the format of an
outcome tree (Figure 1) which provides a qualitative representa-
tion of the disease progression pathways over time by ordering all
relevant health outcomes following infection and illustrating their
conditional dependencies (File S1). Using the incidence- and
pathogen-based DALY approach, all DALYs associated with
current and future health outcomes are assigned to the year of the
initial infection (i.e. the first node of the tree).
In some instances, it was necessary to split a health outcome into
subcategories or ‘health states’, according to their severity to better
represent the true disease burden. We hereby distinguish between
vertical and horizontal disaggregation (for more details see [23]).
Vertical disaggregation is the distribution of health states related to a
specific health outcome, all occurring at the same time period after
infection, into subcategories describing the severity of the health
outcome (e.g. mild and severe gastroenteritis (GE) (Figure 1)).
Horizontal disaggregation describes different health outcomes
occurring sequentially in time in one and the same person, which
are clinically different conditions or diseases (e.g. Reactive arthritis
(Figure 1)).
Choices made in the construction of the outcome trees for the
32 pathogens were based on systematic literature review. Sufficient
evidence of a causal relationship or sufficient evidence of an
association between an infection with a pathogen and sequela was
required for inclusion into an outcome tree.
Disease Burden-model
Incident cases of symptomatic infections at the root of the tree
served as an input for our model, mostly extracted from
(mandatory) surveillance data for notifiable infectious diseases or
equivalent data sources. Input data has to be stratified by age and
sex (File S1).
Incidence-Pathogen DALYs for Infectious Diseases
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However, the incidence is likely not fully represented by raw
data on notified cases owing to the probability of underestimation
of infectious diseases. It is therefore crucial to identify areas and
causes of underestimation and correct for underestimation to
better estimate the incidence.
The overall extent of underestimation can be explained by
two major effects represented by under-ascertainment and
Figure 1. Outcome tree for Campylobacter spp. (a) and Salmonella spp. (b) – an illustration. Note: * Only severe GE cases are at risk to
develop ReA. ** Non-fatal severe GBS cases may develop permanent disability. *** For reasons of simplicity we assume that only severe GBS cases
may be fatal.
doi:10.1371/journal.pone.0079740.g001
Incidence-Pathogen DALYs for Infectious Diseases
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under-reporting [27]. Under-ascertainment refers to cases that do
not seek healthcare advice [27]. Under-reporting, - also including
under-diagnosis -, refers to cases that seek healthcare but for whom
either a specimen was not collected, or for whom a specimen was
collected but did not result in laboratory examination, or whose
infection status was not (correctly) reported to national surveillance
systems [27–28]. Within the BCoDE-project, corrections for
underestimation are applied by using multiplication factor(s)
(MF), representing either correction for underestimation in one
step, or separate correction for under-ascertainment and under-
reporting in two steps (see File S1).
The method used to estimate such MFs depends on the specific
pathogens, the type of data available and the reasons for under-
reporting and under-ascertainment. In general, MFs are devel-
oped by comparing incidence in the general population (deter-
mined by community-based or serological studies (for more details
see [27])) with the number of notified cases extracted from national
or supra-national databases. The choice of MFs was guided by
information from published studies, and complemented by expert
knowledge. MFs must be disease-specific (since under-reporting
and under-ascertainment affects different diseases with varying
magnitudes), country-specific (owing to variations in disease
exposure, surveillance, laboratory practices and healthcare
systems, availability of treatment, as well as cultural, social and
technological differences), and age-specific (since rates of under-
reporting and under-ascertainment can vary widely between age
groups for many diseases), possibly sex-specific, and in some
instances even strain-specific [27].
Having estimated the number of incident cases of symptomatic
infections at the root of the tree, using raw input data adjusted by
MFs (see File S1 for details), incident cases of the subsequent
health outcomes were estimated throughout the outcome tree
using the (conditional) probabilities of progressing from one stage
to the next or to recovery (File S1). If asymptomatic cases also
contribute to disease burden, than the number of incident cases of
symptomatic infections was corrected by a factor t to estimate the
number of all infected cases. t may be age- and/or sex-dependent
(see File S1). Incident cases of the subsequent health outcomes
resulting from asymptomatic cases were also estimated throughout
the outcome tree using the (conditional) probabilities of progress-
ing from one stage to the next or to recovery (File S1). Conditional
probabilities were based on literature review, and may be age- and
sex-dependent. Data necessary for quantitative estimates of disease
burden estimates are often limited, fragmented or based on small
samples, resulting in a considerable degree of uncertainty.
Parameters representing such a lack of perfect knowledge (i.e.
MFs and (conditional) transition probabilities) were explicitly
modelled by incorporating probability distributions, using either
uniform or pert distributions (note Pert distribution is a specific
beta distribution used in risk analysis [29]), and the Monte Carlo
simulation technique to estimate predictive intervals. However, for
parameters that represent inherent heterogeneity of a system as
e.g. differences among patients (i.e. disability weights and duration
of health outcomes), it was decided to use point estimates (i.e.
average). Systematic uncertainty and uncertainty due to lack of
data were explored by sensitivity analysis.
The outcomes of the models are disease burden estimates
expressed in DALYs per year associated with infection with
particular infectious agents and its related sequelae in a particular
country. Data are presented both in aggregated form (DALYs per
year) and in disaggregated form (YLD per year and YLL per year),
from a population perspective (DALY/YLL/YLD per year per
country and per 100,000 population per country) and from an
individual perspective (DALY/YLL/YLD per year per each
infected case). Using a population perspective, DALYs are
stratified into age-classes and sex-classes, and into acute illness
and sequelae.
Data and Data Availability
Mandatory surveillance data for notifiable infectious diseases or
equivalent data sources extracted from national or supra-national
databases (including ECDC databases) and stratified by age and
sex, served as input for our model (File S1). But other data sources
(e.g. own incident estimates (for example using an attack rate to
estimate symptomatic influenza cases); hospitalization data;
mortality data (e.g. variant Creutzfeldt-Jakob disease)) may also
be used as model input in these models. Correction for
underestimation was nearly always required for the selected
pathogens.
Infectious diseases differ in their long-term dynamics and may
display distinct time trends in incidence over years. Incidence of
infectious diseases rarely remains constant for long-time periods,
but decreases (increases) or oscillates over the years, or may have
temporal peaks during outbreak situations. If there is a monoton-
ically decreasing or increasing time trend in incidence, long-term
averages would overestimate or underestimate the disease burden
(see Figure 2.A). And for an infectious agent with an incubation
period and/or latent phase longer than one year (in Figure 2.B for
illustration , 10 years) prevalence data rather than incidence data
from acute infections would lead to an additional overestimation
or underestimation. Therefore to minimise influence of long-term
trends on estimates we based incidence estimates on data from a 3-
year time period. However, for infections with irregular (non-
monotonic) time trends over one or several years, or for diseases
that occur in incidental outbreaks a long-term average (i.e. 10
years) was considered more representative for expected annual
cases.
Application of the Methods for Estimating the Disease
Burden for Campylobacter spp. and Non-typhoidal
Salmonella spp. in the Netherlands
Estimation of the disease burden associated with Campylobacter
spp. and non-typhoidal Salmonella spp. in the Netherlands for the
average of the years 2005–2007 illustrates the presented method-
ology.
Both symptomatic Campylobacter and Salmonella infections in
humans most often result in acute but self-limiting gastroenteritis
(GE) which resolves within a few days, but occasionally GE can be
fatal. Reactive arthritis (ReA), Irritable Bowel Syndrome (IBS) and
Guillain-Barre´ Syndrome (GBS) are the most frequently observed
sequelae of Campylobacter spp. [25–26,30] and were included in our
outcome tree (Figure 1). ReA and IBS are the observed sequelae of
non-typhoidal Salmonella spp. [30–33] (Figure 1). The probability
of developing other post-infectious complications is low and was
therefore disregarded. Given that the duration of diarrhoea
correlates with the risk of developing ReA [34] and that most
evidence on ReA is collected from GE cases requiring medical
service we assume only severe GE cases are at risk of developing
ReA [35]. But given the uncertainty of who is at risk of developing
ReA, sensitivity analysis was conducted, assuming that all GE
cases would be at risk of developing ReA.
Asymptomatic infections with Campylobacter and Salmonella
do not lead to acute illness or sequelae, and are therefore not
considered in our outcome trees. The conditional probabilities for
different health outcomes, following the progression through the
outcome tree, and the distribution of health states over health
outcomes as used in the current study, are summarized in File S2.
Incidence-Pathogen DALYs for Infectious Diseases
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Incident symptomatic Campylobacter spp. cases and incident
symptomatic non-typhoidal Salmonella spp. cases were estimated,
using data from a Dutch sentinel laboratory-surveillance system
[36] (Wilfrid van Pelt, pers. communication; November 2011) and
adjusted for underestimation with country- and pathogen-specific
MFs based on a Swedish travellers study [37]. In this study,
Havelaar et al. [37] calculated incidence rates of Campylobacter
and Salmonella infections and MFs for all European countries
based on disease risks of returning Swedish travellers, anchored to
the Dutch population-based study on gastroenteritis; the Sensor-
study. The MF used for Campylobacter spp. incident cases was
sampled from a pert-distribution with most likely 18.85; minimum
7.4 and maximum 47.4 [37]. And the used MF for non-typhoidal
Salmonella spp. incident cases was sampled from a pert-distribution
with most likely 19.8; minimum 4.4 and maximum 64.8. These
MFs corrected for underestimation (under-ascertainment and
under-reporting) and for coverage of the sentinel surveillance
system, which was 52% (Campylobacter spp.) and 64% (non-
typhoidal Salmonella spp.) [37].
Figure 2. Assuming a downwards time trend for an infection having symptoms in the same years (a) and for an infection where
symptoms occur only after 10 years (b). Note: Blue rectangles represent the number of infections in the year of infection (exposure to an
infection). Green ‘‘cans’’ represent the number of cases with symptoms; where these symptomatic cases occur in the same year as the infection (a.) or
a few years later (b.) as indicated by the dashed arrow. The long-term average (e.g. 10-year average) is highlighted by a light blue oval for incidence,
and by a light green oval for prevalence. The short-term average (e.g. 3-year average) is represented by a dark blue oval for incidence and purple oval
for prevalence.
doi:10.1371/journal.pone.0079740.g002
Incidence-Pathogen DALYs for Infectious Diseases
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Incident cases of other health outcomes were estimated
following the outcome tree using conditional probabilities (File
S2). The disease burden-model was implemented in Microsoft
Excel using @Risk and was run with 10,000 iterations. The results
present the mean and the associated uncertainty boundaries of the
2.5th- and 97.5th-percentiles of the posterior distributions of
outcome variables.
Figure 3. The undiscounted average burden of Campylobacter spp. (a) and Salmonella spp. (b) in the Netherlands (average of 2005–2007) in
DALY per year, subdivided in YLL and YLD for acute illness, sequelae and total. The 95% uncertainty range is shown using error bars.
doi:10.1371/journal.pone.0079740.g003
Incidence-Pathogen DALYs for Infectious Diseases
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Results
The estimated numbers of incident cases of Campylobacter spp.
and non-typhoidal Salmonella spp. were on average 76,520
(95%C.I.: 67,790–85,550) and 35,300 (95%C.I.: 29,250–41,680)
per year in the Netherlands for 2005–2007. Besides acute illness,
both pathogens caused associated numbers of sequelae, on average
6,730 IBS cases (95%C.I.:5,780–7,790), 580 ReA cases (95%C.I.:
335–890) and 42 GBS cases (95%C.I.: 18–67) for Campylobacter
spp. and 3,100 IBS cases (95%C.I.:2,520–3,760) and 183 ReA
cases (95%C.I.: 110–270) for non-typhoidal Salmonella spp.,
respectively. The total disease burden for Campylobacter spp. and
non-typhoidal Salmonella spp., respectively was on average 2,060
DALYs per year (95%C.I.: 1,740–2,410) and 1,190 DALYs per
year (95%C.I.: 910–1,530). Sequelae-associated burden of disease
accounted for 82% and 56% of the total disease burden for
Campylobacter spp. and non-typhoidal Salmonella spp. (Figure 3).
Results are presented in File S2.
If we assume that all GE cases rather than only severe GE cases
are at risk to develop ReA the disease burden increases by 114%
for Campylobacter spp. and by 113% for non-typhoidal Salmonella
spp., respectively (Figure 4).
Discussion
The Methodology
As shown here, the proposed incident- and pathogen-based
approach allows for a comprehensive estimation of the total
disease burden caused by infection with a pathogen. For some
infectious diseases the burden associated with sequelae is higher
than that caused by acute illness. Therefore not considering these
sequelae can therefore lead to considerable underestimation of the
total disease burden, as was the case in most previously conducted
disease burden assessments. Furthermore, the methodology
presented here enables comparisons of disease burden estimates
between infectious diseases, between countries, and with other
health conditions. In this way the estimates can be used to identify
key drivers of infectious disease burden and for priority settings.
The new GBD 2010 study presents prevalence-based DALY
and the authors argue that this approach is more appropriate,
because a) if incidence has declined substantially but prevalence is
still high, this might lead to disadvantages in priority setting for
those diseases, b) the incidence of some chronic conditions is not
precisely measurable (e.g. the start of ischemic heart disease), and
c) the incorporation of co-morbidity is more straightforward [38].
For health services use the prevalence-based DALYs might have
some advantages above our approach. Both methods, if then
accurately modeled, reflect disease burden at a particular point in
time, but from different perspective. However, in case of infectious
pathogens, and in particular for priority settings of interventions to
prevent primary infections, we believe that incidence is the more
suitable input for the DALY metric, because only with the initial
start of the infection is it possible to include all disease sequelae
that result from infection. In particular for infectious diseases with
an upwards or downwards time trend and with an incubation
period and/or latent phase longer than one year, using prevalence
data from sequelae rather than incidence data from acute
infections lead to additional overestimation or and underestima-
tion of burden estimation as was demonstrated in Figure 2. The
incidence- and pathogen based-outcome tree approach avoids the
issue of attributing a proportion of the prevalence of sequelae with
multiple potential causes, such as GBS. The incidence and
pathogen-based approach furthermore allows a proper prediction
of potential effects of interventions aiming at preventing infections,
which is the primary focus in decision making. Using the
prevalence-approach here would lead to different infection times
of infected individuals within the outcome tree making proper
predictions of intervention effects impossible. A last but important
issue is that most surveillance systems for infectious diseases report
incidence and being aware of the possibility to derive prevalence
from incidence, it was decided to use incidence as the appropriate
input.
Figure 4. The undiscounted average burden of Campylobacter spp. and Salmonella spp. in the Netherlands (average of 2005–2007) in DALY
per year, for base case and scenario analysis. DALY are subdivided in YLL and YLD for actue illness, sequelae and total. The 95% uncertainty range is
shown using error bars. Note: ‘‘Base case’’ represents a situation where only severe GE cases are at risk to develop reactive arthritis (ReA). ‘‘SA: ReA’’
represents the scenario analysis where all GE cases are at risk to develop ReA.
doi:10.1371/journal.pone.0079740.g004
Incidence-Pathogen DALYs for Infectious Diseases
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We are not the first using an incidence-based approach (e.g.
[39–42]). In case of infectious diseases most studies, however
derived the incident cases of subsequent health outcomes using
syndrome surveillance combined with etiological fractions, rather
than using conditional probabilities (e.g. GBS [30,43]), or if using
conditional probabilities, not as extensively defined to include all
relevant health outcomes by using conditional probabilities (e.g.
[30,43]). Deriving incident cases of subsequent health outcomes
from syndrome surveillance is definitively a valid approach, but
very time-consuming hampering annual updates of disease
burden. In the approach presented in this paper, the explicit
input in our disease burden model are the numbers of
symptomatic infections. All subsequent health outcomes are
modelled using conditional probabilities. This approach has as
one major advantage, - presuming that conditional probabilities
are properly defined initially -, namely that disease burden
estimations of infectious diseases can easily be updated from year
to year, and could therefore be used, - next to the annual reporting
of surveillance data -, as additional information to decision makers.
And with 32 pathogens in the toolkit that is currently being
developed, health decision makers have evidence-based estimates
to support prioritisation and comparison of infectious diseases.
This methodology also presents opportunities to possibly
improve surveillance. In our experience, the collaboration between
modellers and surveillance staff required to prepare burden
estimates also identifies strengths and weakness of the existing
surveillance system, prompting additional research.
Estimated Disease Burden in the Netherlands
In the Netherlands sequelae-associated burden of disease
contributed to more than 60% of the total disease burden for
both Campylobacter spp. and non-typhoidal Salmonella spp. The
incidence- and pathogen-based DALY approach presented here
allows estimation of the complete burden caused by an infection
and the attribution to specific short- and long-term sequelae.
Due to substantial uncertainties surrounding the MFs the
uncertainty around the estimated incidence and consequently
around the attributable disease burden is large for both pathogens.
The estimates are in line with Havelaar et al. [30], who obtained
an average disease burden of 1,270 DALYs for non-typhoidal
Salmonella spp. for 2009, using a comparable methodology. The
disease burden estimates for Campylobacter spp. are slightly lower
than found by Havelaar et al. [30] (3,250 DALYs), mainly due to
the lower number of estimated incident cases in the years 2005–
2007 as compared to 2009 (i.e. 90,000 cases).
With 2,060 DALYs (Campylobacter spp.) and 1,190 DALYs (non-
typhoidal Salmonella spp.) per year, the impact on the total burden
for Dutch society is relatively low compared to the burden of e.g.
lung cancer (158,100 DALYs per year) and injuries (208,900
DALYs per year) [44]. Both are more comparable to AIDS with
3,800 DALYs per year and influenza with 8,600 DALYs per year
[44].
Potential Limitations of the Applied Methodology
Our approach has several potential limitations. Although
estimates of MFs should be disease, country, age- and sex-specific
relevant data is mostly missing or inconsistent, resulting in MF
estimates that are often only disease- and country-specific.
Consequently, the same MF is used for all age- and sex-classes.
A potential drawback of using notified data, or their equivalents,
corrected with MFs for estimating numbers of symptomatic
incident cases is that those age- and sex-classes with relatively
more notified severe cases are over-represented, and those age-
and sex-classes with relatively fewer notified severe cases are
under-represented. For health outcomes with short-term and self-
limiting illnesses the numbers of incident cases are of major
importance, and over-representation (under-representation) within
specific age- and sex-classes is negligible. However, for infections
with long-term sequelae an incorrect stratification of estimated
incident cases over age- and sex-classes has an impact on the total
disease burden estimates. Over-representing older age-classes, and
under-representing younger age-classes might result in an under-
estimation of the estimated disease burden. Whereas under-
representing older age-classes, and over-representing younger age-
classes results in an overestimation of the total disease burden.
Estimates for MFs are ideally based on community-cohort
studies, but even then uncertainties around the MF estimates are
often huge, resulting in large uncertainty around the disease
burden estimates.
Future research might lead to new evidence on the association
of pathogens with other health outcome(s), and who is at risk of
developing them. More research is necessary for some of the
(conditional) transition probabilities which often remain highly
uncertain.
Conclusion
The methodological framework presented here is an important
tool for generating comprehensive estimates of the disease burden
of infectious diseases in Europe. It enables attribution of burden to
short- and long-term sequelae and provides the basis for
international comparison and prioritization of healthcare resourc-
es.
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